In what experts are calling a potential medical breakthrough, Russia’s new mRNA cancer vaccine, Enteromix, has demonstrated 100% efficacy and safety in clinical trials.
If approved, this treatment could save millions of lives worldwide.
The vaccine, developed by the National Medical Research Radiology Centre and the Engelhardt Institute of Molecular Biology, is now awaiting final approval from Russia’s Ministry of Health.
Once cleared, Enteromix may become the world’s first personalized mRNA-based cancer vaccine available to the public.
Unlike chemotherapy or radiation, Enteromix works by training the immune system to recognize and attack cancer cells.
The vaccine was designed to shrink large tumours, destroy cancer cells, and strengthen the body’s natural defences.
According to RT India, researchers found no serious side effects in patients, who tolerated the treatment well.
This is a major difference from existing therapies that often leave patients weak and struggling with painful complications.
The clinical trials involved 48 participants and were first announced at the St. Petersburg International Economic Forum (SPIEF 2025).
Officials confirmed that after years of research, the vaccine showed consistent effectiveness in stopping tumour growth—and in some cases, completely destroying it.
A MedPath report explained that Enteromix uses four harmless viruses to penetrate and attack cancer cells, while also boosting immune activity.
“Borrowing from the same advanced technology used in COVID-19 vaccines, Enteromix is also personalized to every patient,” researchers noted.
Global oncologists have long argued that a safe and effective cancer vaccine could change the future of medicine.
Enteromix, with its strong trial results, has given new hope to patients, families, and doctors alike.
The only step remaining is regulatory clearance from the Ministry of Health. If approved, Enteromix could soon be available to the public, marking a turning point in cancer treatment.
